Applications of 1,9-Pyrazoloanthrone in Industrial Manufacturing

As a specialized manufacturer of 1,9-Pyrazoloanthrone, we focus on supplying material-quality grades that consistently meet the processing, regulatory, and performance demands in established chemical sectors. The following application scenarios illustrate how this intermediate integrates into established downstream industries, detailing formulation ranges, compliance requirements, stage of process use, and resulting finished goods.

1. Organic Pigment Synthesis for High-Performance Inks

1,9-Pyrazoloanthrone serves as a principal raw intermediate in high-purity pigment manufacture, supporting the production of advanced coloration systems required in printing inks for packaging, security documents, and specialty coatings. It provides a stable backbone for pigment structures used where stringent purity and color strength are mandatory. Our experience in supporting downstream ink manufacturers confirms strict reliance on controlled batch quality and traceability for compliance with end-market regulations concerning food packaging and lightfastness.

Industry compliance standards

• ISO 2846-1: Color and transparency for printing ink pigments
• EN 71-3:2019 on migration of heavy metals in toys (relevant for packaging inks)
• Swiss Ordinance on Materials and Articles in Contact with Food (SR 817.023.21 Art. 35 for pigment applications)
• GMP for Printing Inks (EuPIA GMP, Revision 2021)

Typical usage ratio

• Introduced at 2% to 10% of total pigment mass, adjusted based on solubility and target color index strength

Downstream process integration

• Added during the azo-coupling or condensation step after milling of precursor materials, prior to final laking and finishing

Final product types

• High-performance printing inks (gravure, flexographic)
• Security printing pigments
• Specialty packaging inks for food contact surfaces

2. Pharmaceutical Intermediate for Antitumor Agent Synthesis

In pharmaceutical ingredient manufacturing, 1,9-Pyrazoloanthrone is utilized as a key synthetic intermediate for the preparation of certain kinase inhibitors under GMP-controlled conditions. Its role in the active pharmaceutical ingredient (API) synthesis process necessitates verified impurity profiles and robust material traceability to ensure downstream medicinal compliance. Our production supports contract manufacturers requiring stringent documentation and batch release protocols for preclinical and clinical supply chains.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• USP–NF General Chapter <1078>: Good Manufacturing Practices for Bulk Pharmaceutical Excipients
• 21 CFR Part 210/211: US FDA CGMPs for finished pharmaceuticals
• EU EudraLex Volume 4 (GMP for APIs)

Typical usage ratio

• Dosage varies per synthesis route and specific molecule; typical coupling reactions involve 0.5 to 2 equivalents relative to the reactant core structure

Downstream process integration

• Fed into the multi-step heterocycle-building stage and alkylation reactions under closed-reactor, GMP-compliant processing prior to final API crystallization

Final product types

• Synthetic antitumor agent APIs (e.g., Aurora kinase inhibitors for oncology pipelines)
• Preclinical research compounds for targeted therapy

3. Electronic Grade Dye Intermediate for OLED Materials

Leading electronics and display manufacturers rely on 1,9-Pyrazoloanthrone as a dye intermediate for synthesizing organic compounds with designated optical absorption and emission characteristics within OLED devices. Our controlled synthesis and purified batches minimize trace metal and halogen contamination, supporting long-term display stability and device lifetime—critical for consumer electronics subjected to RoHS and REACH oversight.

Industry compliance standards

• IEC 61249-2-21:2012 (halogen-free requirements for substrates and components)
• RoHS Directive 2011/65/EU (limiting hazardous substances in consumer electronics)
• REACH Regulation (EC) 1907/2006 (registration and SVHC control)
• JEDEC JESD625: Requirements for contamination control in electronic component assembly

Typical usage ratio

• Utilized at 1% to 5% weight basis in organic dye synthesis; final ratio determined by spectral tuning requirements for emitter or host materials

Downstream process integration

• Integrated during the primary dye coupling step, followed by purification and thin-film deposition for OLED layer fabrication

Final product types

• OLED emissive layer materials
• Color conversion films for display panels
• Electronic-grade specialty dyes

4. Advanced Analytical Reagents for Fluorescent Probe Production

Chemical analysis and diagnostics producers employ 1,9-Pyrazoloanthrone in the preparation of highly specific fluorescent probes used for bioimaging, cellular assays, and flow cytometry. This downstream segment prioritizes ultra-low impurity profiles, high batch homogeneity, and analytical traceability, supporting reagent manufacture for regulated life science sectors and clinical diagnostic kits worldwide.

Industry compliance standards

• ISO 13485:2016 (Quality Management Systems for Medical Devices)
• 21 CFR Part 820 (Quality System Regulation for medical devices in the US)
• CLSI Guideline C24: Statistical Quality Control for quantitative measurement procedures
• EU In Vitro Diagnostic Medical Devices Regulation (IVDR EU 2017/746)

Typical usage ratio

• Used as a precursor at 0.1% to 2% mass fraction in fluorescent dye synthesis, with final concentration tailored to probe intensity and stability

Downstream process integration

• Reacted in designated diazo-coupling or substitution reactions under cleanroom-controlled conditions, preceding labeling and conjugation steps

Final product types

• Fluorescent probes for cell analysis
• Labeling reagents for immunological assays
• Diagnostic dyes for flow cytometry applications